JMT202
Phase 2Small molecule
JMT202 is one of 22 small molecule programs targeting Single Ascending Dose. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Cipro
BayerApproved
Lopid
PfizerApproved
Selzentry
GSKApproved
Topamax
WWim Janssens
Approved
Zocor
OOrganon and Co
Approved
Tryngolza (autoinjector)
Ionis PharmaceuticalsPhase 3
Redemplo
Arrowhead PharmaceuticalsPhase 3
SHR-1918
BBeijing Suncadia Pharmaceuticals Co., Ltd
Phase 3
Avandia
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JMT202. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai JMT-Bio Inc.